Celltrion is a South Korean biopharmaceutical company headquartered in Incheon. It develops biological medicines and works with Celltrion Healthcare for global marketing, sales, and distribution.
Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Celltrion said CT-P71 received FDA Fast Track designation for previously treated locally advanced or metastatic urothelial cancer. The ADC candidate is in Phase 1 testing.
Amgen, Celltrion, and Palatin Technologies are advancing obesity drug candidates through clinical development, with trials planned for 2026-2028 targeting liver fat reduction, multiple biological pathways, and rare genetic obesity conditions.
Celltrion announced plans to develop both injectable and oral obesity treatments based on GLP-1, with clinical trial filings planned for 2027 and 2028 respectively.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07533539 |
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy Volunteers |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07367958 |
A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07237516 |
Zymfentra (Infliximab-dyyb) REal World Cohort STudy |
RECRUITING | |
| NCT07200986 |
Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07158346 |
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT07128654 |
A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers |
COMPLETED | PHASE1 |
| NCT07093476 |
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin |
RECRUITING | PHASE3 |
| NCT07054970 |
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT07013578 |
TIDHI Mental Health in IBD Patients Study |
RECRUITING | NA |
| NCT06989723 |
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes |
RECRUITING | PHASE4 |
